Relay Therapeutics

In a recent development, Roche Inc.’s subsidiary Genentech has given notice of termination for a license and collaboration agreement with Relay Therapeutics Inc., affecting the development of an oral small-molecule Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitor, RLY-1971, now known as migoprotafib or GDC-1971 . The termination, effective 180…